During the past decade, Centre Hospitalier de boulogne sur Mer conducted 63 clinical trials. In the 10-year time frame, 63 clinical trials started and 2 clinical trials were completed, i.e. on average, 3.2% percent of trials that started reached the finish line to date. In the past 5 years, 25 clinical trials started and 2 clinical trials were completed. i.e. 8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre Hospitalier de boulogne sur Mer" #1 sponsor was "University Hospital, Lille" with 18 trials, followed by "Federation Francophone de Cancerologie Digestive" with 17 trials sponsored, "UNICANCER" with 8 trials sponsored, "The Lymphoma Academic Research Organisation" with 7 trials sponsored and "Groupe Francophone des Myelodysplasies" with 7 trials sponsored. Other sponsors include 42 different institutions and companies that sponsored additional 38 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre Hospitalier de boulogne sur Mer" #1 collaborator was "GERCOR - Multidisciplinary Oncology Cooperative Group" with 4 trials as a collaborator, "Ministry of Health, France" with 4 trials as a collaborator, "UNICANCER" with 4 trials as a collaborator, "Federation Francophone de Cancerologie Digestive" with 3 trials as a collaborator and "National Cancer Institute, France" with 3 trials as a collaborator. Other collaborators include 100 different institutions and companies that were collaborators in the rest 95 trials.

According to Clinical.Site data, the most researched conditions in "Centre Hospitalier de boulogne sur Mer" are "Breast Cancer" (6 trials), "Myelodysplastic Syndromes" (5 trials), "Colorectal Cancer" (4 trials), "Metastatic Colorectal Cancer" (4 trials) and "Pancreatic Cancer" (4 trials). Many other conditions were trialed in "Centre Hospitalier de boulogne sur Mer" in a lesser frequency.

Most popular intervention types in "Centre Hospitalier de boulogne sur Mer" are "Drug" (56 trials), "Other" (24 trials), "Procedure" (9 trials), "Device" (7 trials) and "Behavioral" (6 trials). Other intervention types were less common.

The name of intervention was led by "fluorouracil" (6 trials), "gemcitabine hydrochloride" (5 trials), "Bevacizumab" (4 trials), "Gemcitabine" (4 trials) and "LV5FU2" (3 trials). Other intervention names were less common.

The vast majority of trials in "Centre Hospitalier de boulogne sur Mer" are 96 trials for "All" genders and 7 trials for "Female" genders.

Currently, there are NaN active trials in "Centre Hospitalier de boulogne sur Mer". 1 are not yet recruiting, 25 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 58 completed trials in Centre Hospitalier de boulogne sur Mer, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Centre Hospitalier de boulogne sur Mer, 1 "Phase 1" clinical trials were conducted, 30 "Phase 2" clinical trials and 32 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 17 trials that are defined as “Not Applicable".